Introducing the Syn-One Clinician Network™
Click here to access the Syn-One Clinician Network, a directory of some of the hundreds of neurologists who are using the Syn-One Test® to aid in the diagnosis of Parkinson’s disease and other neurological disorders.

Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test® to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND has launched the Syn-One Test® to offer physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy. And our mission has just begun.
Learn More

Introducing the Syn-One Test® from CND Life Sciences

Offering physicians and patients an accurate, evidence-based tool to help confirm a diagnosis of a synucleinopathy.

seal icon

CLIA-Certified Pathology Lab

test tube icon

Dedication to Science & Research

DNA icon

Patient-Focused Mission

microscope icon

Quality & Reliability at Our Core

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
March 20, 2023

Using Cutaneous Synuclein Biosignatures to Distinguish Parkinson’s Disease From Multiple System Atrophy

A recent paper published in Neurology and co-authored by two of CND Life Sciences’ co-founders,…
Insights
March 13, 2023

CND Life Sciences Invests in Talent Via Internship Program

As CND Life Sciences continues to experience growth, launch new diagnostic tests, and expand its…
Insights
February 16, 2023

Minimally Invasive, Maximally Important

Neurodegenerative diseases like Parkinson’s and dementias continue to represent some of the most significant threats…
VIEW ALL INSIGHTS

Check out press releases, news alerts and coverage of CND happenings.

News Release
March 22, 2023

CND Life Sciences Enters into Licensing and Collaboration Agreement to Advance Diagnostic Technology for Neurodegenerative Diseases

Agreement with Beth Israel Deaconess Medical Center Solidifies Important Technology for CND’s Syn-One Test® and…
On Our Radar
March 6, 2023

Non-Surgical Ultrasound Procedure Improves Parkinson’s Motor Symptoms

Research published last month in the New England Journal of Medicine demonstrated that a focused…
On Our Radar
February 24, 2023

Neuron Replacement Therapy for Parkinson’s to Advance to Clinical Testing

San Diego-based Ryne Biotechnology announced last week that it has received a $4 million Clinical…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our free Skin Biopsy Test Kit, simply collect three small skin biopsies from your patient, send them to our CLIA-certified lab, and CND will provide important visual insights to support a diagnosis.

Order a Kit